Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe Hofman et al. EquipePC 2023-10
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Tarantino et al. EquipeCTCS 2023-08
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Barlesi et al. EquipeAM Jan 14 2016
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy Leconet et al. PlateformePP2I Nov 20, 2014
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact Nabholtz et al. EquipeELC Aug 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeMY Aug 30 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeCTCS Aug 30 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipePM Aug 30 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeCG Aug 30 2014


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés